Transgenic mice with epidermal overexpression of VGLL3 develop lupus-like systemic disease and provide a tool for identifying therapeutic targets and investigating how epithelial–immune cell interactions precipitate systemic autoimmunity. This evidence concerns the gene VGLL3 and systemic lupus erythematosus.